Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

42. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Harrington AR, Armstrong EP, Nolan PE, Malone DC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) . Interventions The four interventions were warfarin, apixaban 5mg twice daily, dabigatran 150mg twice daily, and rivaroxaban 20mg once daily. Warfarin dose was assumed to be adjusted to achieve the patient's target international normalised ratio (INR). Location/setting USA/in-patient and out-patient care. Methods Analytical approach: A Markov model, with one-month cycles, combined the published data. The time horizon was 30 years and the authors stated that the perspective was societal. Effectiveness data

NHS Economic Evaluation Database.2013

43. Meta-analysis of rivaroxaban and bleeding risk

Meta-analysis of rivaroxaban and bleeding risk Meta-analysis of rivaroxaban and bleeding risk Meta-analysis of rivaroxaban and bleeding risk Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ CRD summary This review concluded that with a decrease in fatal bleeding and no suggestion of an increase in all-cause mortality, rivaroxaban has a favourable bleeding-related safety profile. This is an appropriate conclusion but without a comparison of both efficacy and safety in these trial populations (...) it would be difficult to make clinical judgements regarding the use of rivaroxaban. Authors' objectives To compare the safety of rivaroxaban and vitamin K antagonists (VKA), with a particular focus on bleeding and mortality. Searching MEDLINE, EMBASE, CINAHL, The Cochrane Library and Science Citation Index Expanded were searched from inception to May 2012. There were no language restrictions. Search terms were reported. Unspecified clinical trial registries were searched. Conference proceedings were

DARE.2013

44. Clinical outcomes with rivaroxaban in patients transitioned from vitamin k antagonist therapy: a subgroup analysis of a randomized trial.

Clinical outcomes with rivaroxaban in patients transitioned from vitamin k antagonist therapy: a subgroup analysis of a randomized trial. BACKGROUND: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation. OBJECTIVE (...) : To determine the efficacy and safety of rivaroxaban compared with warfarin among vitamin K antagonist (VKA)-naive and VKA-experienced patients. DESIGN: Prespecified subgroup analysis. (ClinicalTrials.gov: NCT00403767 ). SETTING: Global. PATIENTS: 14,264 persons with atrial fibrillation. MEASUREMENTS: Interaction of the relative treatment effect of rivaroxaban and warfarin on stroke or systemic embolism among VKA-naive and VKA-experienced patients. RESULTS: Overall, 7897 (55.4%) patients were VKA

Annals of Internal Medicine2013

45. Rivaroxaban (Xarelto) - treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults

Rivaroxaban (Xarelto) - treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults

Scottish Medicines Consortium2013

46. Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment

Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Article Text Therapeutics Randomised controlled trial Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non

Evidence-Based Medicine (Requires free registration)2013

47. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients. 23388003 2013 02 07 2013 02 14 2015 11 19 1533-4406 368 6 2013 Feb 07 The New England journal of medicine N. Engl. J. Med. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. 513-23 10.1056/NEJMoa1111096 The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy (...) and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary efficacy outcomes were

NEJM2013

48. New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?)

New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?) New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) From: Therapeutic area: Risk of serious haemorrhage—clarified contraindications apply to all 3 medicines. Article update September 2016 (...) thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation. Apixaban (Eliquis ▼) and rivaroxaban (Xarelto ▼) are direct, highly selective, orally active inhibitors of activated factor X (factor Xa). All 3 new oral anticoagulants are licensed for: prevention of venous thromboembolic events in adults who have had elective total hip-replacement or knee-replacement surgery prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more

MHRA Drug Safety Update2013

49. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | Guidance and guidelines | NICE Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Technology appraisal guidance [TA287] Published date: 26 June 2013 Share Save Guidance on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further

National Institute for Health and Clinical Excellence - Technology Appraisals2013

51. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of rivaroxaban versus enoxaparin for prevention of venous thromboembolism in patients who underwent major orthopaedic surgery such as total hip or total knee replacement

NHS Economic Evaluation Database.2012

52. Rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE.

Rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation (...) manager Format Create File 1 selected item: 22910960 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Aug 21;157(4):JC2-6. doi: 10.7326/0003-4819-157-4-201208210-02006. ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. 1 . 1 Kaiser Permanente Colorado, Aurora, Colorado

Annals of Internal Medicine2012

53. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic (...) for the use of new oral anticoagulants for prophylaxis against venous thromboembolism after total hip or knee replacement. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to April 2011. Clinical trial registries, relevant conference proceedings and websites of regulatory agencies were searched. The search strategy was available online. There were no language restrictions. Study selection Randomised controlled trials (RCTs) that compared rivaroxaban (10mg

DARE.2012

55. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Bjorholt I Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of rivaroxaban versus two low-molecular-weight heparin (LMWH) treatments (enoxaparin and dalteparin) for the prevention of venous thromboembolism, after total hip or knee

NHS Economic Evaluation Database.2012

56. Rivaroxaban (Xarelto) - the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation

Rivaroxaban (Xarelto) - the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation

Scottish Medicines Consortium2012

58. Randomised controlled trial: For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding

Randomised controlled trial: For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you (...) are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing

Evidence-Based Medicine (Requires free registration)2012

59. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Miller CS, Grandi SM, Shimony A, Filion (...) %. New oral anticoagulants investigated included apixaban, dabigatran and rivaroxaban. Varying proportions of patients had previously experienced stroke, transient ischaemic attack, heart failure, diabetes mellitus and/or hypertension at baseline. The authors did not report how many reviewers selected the studies for inclusion. Assessment of study quality The Cochrane Collaboration's tool was used to assess risk of bias as low, high or unclear for the following quality domains: Sequence generation

DARE.2012

60. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C CRD summary (...) All-cause deaths were equivalent for each treatment, but apixaban and dabigatran 110mg seemed to prevent more strokes, with least risk, for patients with non-valvular atrial fibrillation; dabigatran 150mg seemed better for patients at high risk of embolism. The review was generally poorly reported. The indirect comparisons and potential for confounding mean that the conclusions may not be reliable. Authors' objectives To compare the efficacy and safety of dabigatran, rivaroxaban, and apixaban

DARE.2012